Skye Bioscience, Inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against Skye Bioscience, Inc. (SKYE)

If you purchased or acquired Skye Bioscience securities and suffered losses, you may be eligible to join this securities investigation and seek compensation.

About Skye Bioscience

Skye Bioscience is a clinical-stage biotechnology company focused on developing pharmaceutical products for the treatment of obesity and other metabolic disorders.

The company’s lead asset is nimacimab, a cannabinoid receptor type 1 (CB1) inhibitor that Skye Bioscience positioned as a novel approach to weight loss and metabolic health.

Potential Concerns Under Investigation

Lawyers are investigating whether Skye Bioscience made misleading statements about its lead drug candidate nimacimab from August 2024 through early-October 2025.

In August 2024, Skye Bioscience launched its Phase 2 obesity trial, calling nimacimab a "next-generation weight loss therapeutic" that would "safely and effectively reduce weight in patients with obesity." The company allegedly maintained this optimistic tone throughout the class period.

In March 2025, management highlighted preclinical data showing "significant dose-dependent weight loss" and described "potentially compelling attributes." In May 2025, the company cited mouse model data and claimed nimacimab "continues to demonstrate a differentiated profile as a potential weight loss therapy."

On October 6, 2025, Skye Bioscience disclosed that nimacimab monotherapy "did not achieve the primary endpoint of weight loss" and drug exposure was "lower than expected." The stock plummeted approximately 60% in one day from $4.75 per share at market close on October 3 to $1.90 per share on October 6, 2025, causing substantial harm to investors.

Attorneys may examine whether the company's alleged optimistic public statements adequately disclosed clinical trial risks, the consistency between management's communications and internal knowledge about trial progress, and potential financial incentives tied to nimacimab as the lead asset that may have motivated misrepresentations.

Lawyers are also reviewing whether investors were misled about the drug's likelihood of success before the dramatic stock collapse following the failed trial results.

Your Rights and Next Steps

This is an active investigation into potential securities law violations by Skye Bioscience. Investors who purchased or acquired Skye Bioscience securities between August 2024 and October 2025, and suffered losses may have legal rights.

If the investigation uncovers evidence of misleading statements, omissions, or other misconduct, it could lead to a class action lawsuit seeking to recover damages for affected investors.

Investors should be aware that joining a securities investigation is a time-sensitive matter. Lawyers are ready to help investors understand their rights, evaluate their losses, and determine eligibility to participate in any future class action. By joining the investigation, investors may be able to help shape the outcome and potentially recover compensation for their losses.

You May Be Entitled to Compensation

If you purchased or acquired Skye Bioscience securities during the relevant period, you may be eligible to join this investigation and seek compensation. Securities investigations are time-sensitive, and acting promptly can help preserve your rights.

To participate in the investigation or to learn more about your options, complete the form below.